FDA: Don't Use Azithromycin for Lung Condition in Cancer Patients

The U.S. Food and Drug Administration released a warning for clinicians about an increased risk of relapse and death among patients with hematologic malignancies who receive azithromycin to prevent bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. The ALLOZITHRO trial analyzed 480 patients across 13 months and observed relapse in 32.9% of patients compared with 20.8% on placebo. Ninety-five patients in the treatment group died vs 66 in the placebo group. The study was stopped after 2 years.